Table I.
Clinicopathological features of patients with renal cell carcinoma.
| ID | Gender | Age | Histological type | Response | Group | Prediction |
|---|---|---|---|---|---|---|
| KIS-020 | M | 63 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-021 | F | 71 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-028 | M | 71 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-034 | M | 55 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-035 | F | 74 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-038 | M | 63 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-044 | M | 66 | Clear cell carcinoma | CR | Responder | Learning |
| KIS-050 | M | 60 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-058 | M | 56 | Clear cell carcinoma | PR | Responder | Learning |
| KIS-061 | M | 65 | Clear cell carcinoma | CR | Responder | Learning |
| KIS-001 | M | 69 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-005 | M | 25 | Combined type (cyst-associated and papillary renal cell carcinoma) | PD | Non-responder | Learning |
| KIS-006 | M | 44 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-007 | M | 71 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-008 | M | 67 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-016 | F | 67 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-026 | M | 64 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-032 | M | 60 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-040 | F | 68 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-046 | M | 51 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-048 | M | 67 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-049 | F | 51 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-051 | M | 73 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-052 | F | 71 | Combined type (clear cell, granular cell and spindle cell carcinoma) | PD | Non-responder | Learning |
| KIS-057 | F | 60 | Clear cell carcinoma | PD | Non-responder | Learning |
| KIS-059 | M | 60 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-060 | M | 56 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-066 | M | 61 | Clear cell carcinoma | NC | Non-responder | Learning |
| KIS-012 | M | 62 | Clear cell carcinoma | PR | Responder | Test |
| KIS-029 | F | 57 | Clear cell carcinoma | PR | Responder | Test |
| KIS-043 | M | 64 | Clear cell carcinoma | PR | Responder | Test |
| KIS-045 | M | 62 | Papillary renal cell carcinoma | PR | Responder | Test |
| KIS-065 | F | 39 | Combined type (clear cell carcinoma and spindle cell carcinoma) | PR | Responder | Test |
| KIS-003 | F | 56 | Clear cell carcinoma | NC | Non-responder | Test |
| KIS-004 | M | 58 | Clear cell carcinoma | MR | Non-responder | Test |
| KIS-015 | M | 40 | Clear cell carcinoma | NC | Non-responder | Test |
| KIS-023 | M | 71 | Clear cell carcinoma | MR | Non-responder | Test |
| KIS-030 | F | 51 | Clear cell carcinoma | NC | Non-responder | Test |
| KIS-033 | M | 72 | Clear cell carcinoma | PD | Non-responder | Test |
| KIS-047 | M | 76 | Clear cell carcinoma | MR | Non-responder | Test |
| KIS-056 | M | 69 | Clear cell carcinoma | MR | Non-responder | Test |
| KIS-064 | M | 61 | Clear cell carcinoma | PD | Non-responder | Test |
Response, response to IL-2 and IFN-α combination therapy for RCC with lung metastasis; Responder, CR or PR; Non-responder, PD, NC or MR. CR, complete response (shrinkage rate 100%); PR, partial response (shrinkage rate ≥50 to <100%); MR, minor response (shrinkage rate ≥25 to <50%); NC, no change (shrinkage rate ≥−25 to <25%); PD, progressive disease (shrinkage rate ≤−25%). Shrinkage rate, tumor shrinkage rate in pulmonary metastasis.